Prognostic Value of Serum CA 125 Measurment during Chemotherapy for the Patients with Epithelial Ovarian Cancer.
- Author:
Eung Seon KIM
1
;
Seon Ho KIM
;
Seon Kyung LEE
;
Seung Bo KIM
Author Information
1. Department of Obstetrics and Gynecology, College of Medicine, Kyung Hee University, Seoul, Korea.
- Publication Type:Original Article
- MeSH:
Drug Therapy*;
Humans;
Laparotomy;
Neoplasm, Residual;
Ovarian Neoplasms*;
Palliative Care
- From:Korean Journal of Obstetrics and Gynecology
1997;40(11):2402-2408
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Serum CA 125 was measured during early chemotherapy in 34 patients from January, 1991 to December, 1994 with ovarian cancer to investigate if serial measurmemts of antigen level could be used as a prognostic parameter. Serum CA 125 was determined after the first, second, and third course of chemotherapy. There was significant correlation between high serum CA 125 levels(>35U/ml) after the third course of chemotherapy and advanced FIGO stage, large residual tumor volume after cytoreductive surgery, but there was no significant correlation with patient age, tumor differentiation, and hitologic type. And high serum level of CA 125 after the third course of chemotherapy was significantly correlate with poor response to chemotherapy(p<0.0001), but there was no significant correlation with the finding of second-look laparotomy. CA 125 was a significant parameter in all three courses of chemotherapy but its correlation with 5-year survival was improved with the number of courses of the chemotherapy. Patientswith high serum CA 125 level(>35U/ml) after the third course had a 0% 5-year survival. This should be compared with a 89.5% 5-year survival in patients who had serum CA 125 level of 35U/ml or less(p<0.0001). As a consequence of this study, chemotherapy of patients with high CA 125 levels after the third course may be discontinued and replaced by other chemotherapy or palliative therapy.
